Clinical Trial Update: Study of BPI-572270 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS [Phase 1, Phase 2]

View source ↗

Summary

Betta Pharmaceuticals' BPI-572270 is being studied in Phase 1/2 trials for advanced solid tumors with specific RAS mutations, including non-small cell lung canc…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer
• Non-small Cell Lung Cancer
• Pancreatic Ductal Adenocarcinoma

Drugs mentioned

• BPI-572270

Snippet

Sponsor: Betta Pharmaceuticals Co., Ltd. | Conditions: Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC) | Phase 1, Phase 2 | Status: NOT_YET_RECRUITING